Explore the words cloud of the FURTHER project. It provides you a very rough idea of what is the project "FURTHER" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||4˙018˙187 €|
|EC max contribution||3˙998˙125 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||971˙312.00|
|2||THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL||UK (LONDON)||participant||756˙192.00|
|3||KLINIKUM DER UNIVERSITAET ZU KOELN||DE (KOELN)||participant||646˙415.00|
|4||VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA||FI (TURKU)||participant||430˙250.00|
|5||STICHTING ISALA KLINIEKEN||NL (ZWOLLE)||participant||386˙250.00|
|6||ISTITUTO ORTOPEDICO RIZZOLI||IT (BOLOGNA)||participant||280˙835.00|
|7||CENTRO SA.NA. SERVIZI SANITARI PRIVATI SRL||IT (APRILIA)||participant||260˙625.00|
|8||UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA||IT (ROMA)||participant||158˙750.00|
|9||ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA||IT (BOLOGNA)||participant||107˙495.00|
|10||FOCUSED ULTRASOUND FOUNDATION||US (CHARLOTTESVILLE)||participant||0.00|
Bone metastases are a common manifestation of advanced cancer, with pain as a devastating consequence. Due to rising cancer incidence rates and improving survival, the number of cancer patients living long enough to develop bone metastases is increasing rapidly. Metastatic bone pain is difficult to manage and has a detrimental impact on quality of life of patients, their partners and care-givers.
Radiation therapy (RT), the standard treatment for palliation of metastatic bone pain, is easy to administer and well tolerated. However, RT is only effective in 60-70% of patients and usually takes four weeks before inducing pain response. Inadequate pain relief is therefore common and alternative treatment options are urgently needed.
Pain palliation may be substantially improved by including MR-HIFU as alternative or in addition to RT. Preliminary studies suggest that MR-HIFU induces rapid pain relief (within days), and may palliate pain in patients in whom RT is not effective. Currently, strong evidence and context is lacking for wide-spread implementation of MR-HIFU into routine care.
The FURTHER project aims to demonstrate (cost)effectiveness of MR-HIFU as an alternative or additional treatment option to relief metastatic bone pain. For this purpose, a three arm international randomized controlled trial (RCT) including 216 patients will be conducted comparing early and late pain response in patients treated with RT only, MR-HIFU only, and RT with MR-HIFU. A prediction model will be developed to identify patients who are likely to benefit from MR-HIFU in order to allow (cost-) effective use of the treatment. A pilot pathway RCT will be conducted to explore the effectiveness of MR-HIFU as part of a comprehensive pain management strategy. Finally, FURTHER will map and analyse socio-economic barriers for integration of MR-HIFU in routine care in the wider European context and make recommendations on how to provide equal access to this promising new treatment.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FURTHER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FURTHER" are provided by the European Opendata Portal: CORDIS opendata.
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccinationRead More
Global Alliance for Chronic Diseases SecretariatRead More